Abstract: The quantification of frequency of IFN-γ-producing T cells responding to donor alloantigen using the IFN-γ enzyme linked immunosorbent spot (ELISPOT) holds potential for pretransplant and posttransplant immunological risk stratification. The effectiveness of this assay, and the ability to compare results generated by different studies, is dependent on the utilization of a standardized operating procedure (SOP). Key factors in assay standardization include the identification of primary and secondary antibody pairs, and the reading of the ELISPOT plate with a standardized automated algorithm. Here, we describe in detail, an SOP that should provide low coefficient of variation results. For multicenter trials, it is recommended that groups perform the ELISPOT assays locally but use a centralized ELISPOT reading facility, as this has been shown to be beneficial in reducing coefficient of variation between laboratories even when the SOP is strictly adhered to.
Abstract: The quantification of frequency of IFN-γ-producing T cells responding to donor alloantigen using the IFN-γ enzyme linked immunosorbent spot (ELISPOT) holds potential for pretransplant and posttransplant immunological risk stratification. The effectiveness of this assay, and the ability to compare results generated by different studies, is dependent on the utilization of a standardized operating procedure (SOP). Key factors in assay standardization include the identification of primary and secondary antibody pairs, and the reading of the ELISPOT plate with a standardized automated algorithm. Here, we describe in detail, an SOP that should provide low coefficient of variation results. For multicenter trials, it is recommended that groups perform the ELISPOT assays locally but use a centralized ELISPOT reading facility, as this has been shown to be beneficial in reducing coefficient of variation between laboratories even when the SOP is strictly adhered to. P retransplant rejection risk stratification is currently determined by assessment of donor-specific antibodies, using the complement dependent cytotoxicity and solid phase (luminex and flow cross match) assays. These assays focus on humoral sensitization to HLA 1 or non-HLA antigens, 2 and have been standardized across laboratories globally through the availability of commercially validated assay protocols, reagents and equipment.
Although the critical role for T lymphocytes (T cells) in allograft rejection has been long known, T cell sensitization is not routinely measured. A number of shortcomings have limited broader utilization of assays measuring the reactivity of T cells to foreign HLA molecules (allospecific reaction). In particular, these assays have been difficult to standardize between laboratories, are technically, monetarily and timewise challenging to perform, require a source of donor antigens to act as stimulators and have a high intralaboratory and interlaboratory coefficient of variation (CV) in excess of 40% despite centralized counting methods. 3 At present, there is only limited evidence that even the most reproducible assays of T cell reactivity are able to accurately predict acute rejection.
The most basic T cell reactivity measurement assay is a mixed lymphocyte reaction (MLR). In this assay, the pair of responding cells (often a mixture of peripheral blood mononuclear cells [PBMCs] from a transplant recipient) are cultured with cell-cycle arrested, stimulating cells (irradiated B cells or other antigen presenting cells from a transplant donor), and proliferation of the recipient's cells are measured. However, the MLR assay has not been shown to have a predictive value posttransplant. 4, 5 A more sophisticated descendent of the MLR assay is the enzyme-linked immunosorbent spot (ELISPOT) assay that quantifies the frequency of responder cells detected by their secretion a cytokine or other molecule (see Figure 1) . 6, 7 In transplant immunology, this assay was used initially by Heeger et al 8 in a murine transplantation model to examine the direct and indirect T cell alloresponse in rejection. It was found that when a mouse donor and recipient pair were completely MHC mismatched, the direct alloresponse predominated with the recipient's alloreactive T cells to intact MHC molecules on donor cells. In contrast, when stimulator cells were derived from donor x recipient F1 mice then alloreactive T cells recognized intact donor MHC as well as donor-derived MHC antigens presented on recipient-matched MHC. Alloreactive T cells were identified and quantified in this assay by their secretion of effector cytokines notably IFN-γ. For clinical studies, when using intact fully-HLA mismatched donor cells as stimulators, this assay predominantly measures the frequency of T cells recognizing intact donor MHC molecules and not T cells capable of indirect recognition. However, a recent report by Shiu et al 9 revealed that the use of donor-cell lysates can detect indirect T cell alloreactivity in patients with chronic antibody-mediated rejection. The interest in quantifying T cells that directly and indirectly recognize and respond to donor-MHC stems from the hypothesis that these populations of T cells play distinct roles in early acute rejection versus late, chronic rejection. 10, 11 The development of the ELISPOT assay into a reliable and replicable scientific and clinical tool for measurement of T cell alloresponse has been challenging for multiple reasons. To accurately measure the frequency of alloreactive T cells in recipient's blood specifically against a donor organ, donor cells and tissues have to be preserved at the time of transplantation, and stored using protocols that allow these cells to be recovered many years after transplantation to be used as donor-specific stimulators. Donor-derived PBMC and splenocytes can provide a source of specific donor antigens 11, 12 and are likely the most accurate representation of an individual's alloresponse to the graft. If donor-derived PBMC and splenocytes are of limited supply, a renewable source of expanded donor-derived B cells may be used. Indeed, Zand et al 12 reported that in vitro expanded B cells stimulated a similar cytokine profile in CD4 + T cells as unfractionated PBMC. Finally, for patients who have been transplanted many years prior, donor-specific stimulators may be difficult to acquire. This has led to utilization of a panel of third party stimulators (B cells enriched and expanded from PBMC) with diverse HLA expression for clinical trials. 13, 14 The cost and logistics for such an endeavor are significant barriers to the translation of these assays into standard clinical practice, and there is a strong need for more user-friendly sources of donor HLA antigens if this assay is to be used routinely in the clinic.
Although the ELISPOT assay can measure a variety of elaborated cytokines by memory and/or naive T cells, only the IFN-γ ELISPOT has undergone extensive international interlaboratory validation in the transplantation setting. 3, 11, 15 Using this assay, it has been shown that high frequencies of alloreactive T cells prior to transplantation correlates with increased risk of acute rejection. 8, 13, 16 Bestard and colleagues 11 reported that patients with late acute rejection also had higher frequencies of IFN-γ-producing T cells. Finally, this assay has also been reported to predict graft rejection. 10 Conversely low frequency of such cells posttransplantation has been associated with the development of complications of immunosuppression namely infection and malignancy.
14 The CTOT-01 multicenter study recently reported on the utility of pre-transplant IFN-γ ELISPOT test as a risk-stratifying biomarker for kidney transplant injury. 15 In the kidney transplant recipients who did not receive T cell-depleting, rabbit antithymocyte globulin induction therapy, higher IFN-γ ELISPOT positivity was correlated with lower estimated glomerular filtration rate at 6 and 12 months posttransplantation. These data suggest that the IFN-γ ELISPOT assay, when used longitudinally and within the context of an induction therapy without T cell depletion, can identify patients for which maintenance immunosuppression may have to be modified to improve outcomes.
Here, we provide a standard operating protocol (SOP) for IFN-γ ELISpot assay that was consolidated from different sources, namely the CTOT, ITN, and ONE studies, and the human immunology cores of the University of Chicago, University of Pennsylvania and Centre for Clinical and Experimental Transplantation, Adelaide. Comprehensive discussion of the variables affecting the ELISPOT production process has been published elsewhere (see Ashoor et al, 3 Bestard et al, 11 and Janetzki et al 17 )
. In this SOP, we have attempted to identify the multiplicity of variables that can affect the production of and the quantification of the IFN-γ spots. We note that in populations or patients in whom a high spot count is expected and it is desirable to differentiate the highest responders, it is possible to achieve reproducibly accurate spots counts with dilution methods. By reducing the number of responder cells while keeping the same number of stimulators, hence the antigenic density within the assay remains the same, we found that there was a low degree of variation (CV ≤ 0.2) between the IFN-γ ELISPOT results (see Figure 2A) .
Previous validation studies have demonstrated a clear benefit to centralized counting method, and this is the recommended method for counting of produced ELISPOT plates for multinational, multicenter trials. 3 For interim data analysis, local counts strongly correlate with a centralized spot counts despite differences in both operator procedures and ELISPOT reading software (see Figure 2B ). However, to enable interlaboratory comparison for multi-national trials, we have relied on a single site counting method. In this SOP, we provide a recommended starting point for counting of the spots based on our laboratories' experiences. We believe with increasing laboratory experience of spot counting, a robust SOP and periodic quality control comparison of local and central counts a good correlation between centers may be achievable. to global virtual laboratory standard operating procedures for blood collection, PBMC isolation and storage, PBMC counting on hemocytometer and PBMC thawing. 18 (a) When thawing frozen cells, add 5 μl of benzonase to 25 mL of 1%Human AB serum in RPMI (containing glutamine and penicillin-streptomycin). Cells can be used immediately, however it has been reported that overnight culture of thawed cells improves the quality of the ELISPOT response. /mL (100,000 cells/well) 5. Plating Cells (a) Invert the plate after the final wash. Mix cells thoroughly by gently pipetting, and add cells to the appropriate wells. We recommend performing the assay in triplicate: background (responder cells alone), alloresponse (stimulator and responding cells) and positive control (PHA + responder cells). We have observed no response from well prepared stimulators, in the IFN-γ assay and thus a control well is not required. However, for other cytokines it may be necessary to investigate background spots for stimulators. (i) Use large orifice tips (Fisher Scientific, 02707134) to add 100 μL of responders to the plate (300,000 cells/well), and then 100 μL of stimulators (100,000 cells/well). (ii) Be sure to add 100 μL of media or PHA to control wells.
Media-only controls are necessary to assess background cytokine production, whereas the PHA wells confirm the viability of the responder cells. (b) Check to make sure that all the wells have 200 μL media.
Holding the plate in one hand, gently tap the sides of on all 4 sides of the plates to redistribute the cells. This is important because otherwise the spots tend to cluster around the edges of the wells and making it harder to count. (c) Incubate the plate at 37°C in the CO 2 humidified incubator for 24 hours. It is critical that the plate is not disturbed during this incubation as this may lead to the blurring of the spots. Finally, do not stack the plates to ensure that the temperature of the plates is uniform. (c) Working Solution (i) An entire plate requires 800 μL of AEC to be added to 24 mL of AEC buffer, and then the solution is filtered using a 0.45-μm filter. (ii) Add 12 μl H 2O2 to each well; this must be added last.
(3) If stimulators are NOT B cell enriched, they must be irradiated for 12 minutes at 3000 rads/min. Irradiated cells must be centrifuged again at 7 minutes, 1200 rpm, brake on and then the cell concentration adjusted to 3 x 10 6 /mL using cRPMI + 1% human AB serum. (4) Prewetting might help ensure coating efficiency in some instances. Prewet plates with 70% ethanol, wash well with PBS 3 times afterward, and then follow the recommended protocol. Critical aspects of the SOP 1. It is critical that when pipetting solutions into the 96 well plate, the pipette tip does not touch the delicate membrane well bottom and a slow pipetting technique should be used for adding cells and solutions to the wells. 2. A major factor in successful frequency analysis for cytokines using ELISPOT is the availability of high-affinity purified anticytokine antibodies that are directed against different epitopes on the cytokine molecule. 3. Because IFN-γ (and other cytokines) is not constitutively expressed, it is important to determine the optimal type, strength, and duration of stimulus that induces each cytokine. A control set of unstimulated cultures is necessary to determine the rate of spontaneous IFN-γ production. 4. Careful timing of both cell incubation and signal development is crucial for maximizing the signal to noise ratio. 5. T cells can recognize HLA alloantigen directly or indirectly.
Direct allorecognition is measured by coculture with intact donor cells. Indirect allorecognition is much more challenging to measure, and some groups have successfully used donor-cell lysates. 6. Titration (1:2) of responding cells will allow a more accurate determination, especially when the frequency of IFN-γ-producing cells is very high. 7. Thorough blocking, washing and draining of the plates are necessary to reduce background. 8. Although not part of the cellular assay per se-the settings on the ELISPOT reader and the type of ELSIPOT reader can have profound effect on the results of these assays-consider a centralized plate-reading strategy for multicenter trials. 9. Time considerations (a) Although washing the plates takes only a few minutes, plates should be incubated with antibody ≥4 hr at room temperature or 18 to 24 hours at 4°C for optimum sensitivity. (b) Once the assay is completed, the spots can be counted at the convenience of the investigator. Although spots develop in a few minutes, they become more distinct after 24 hours and tend not to fade over time if the plates are wrapped in foil and kept at room temperature. 10. Patient populations (a) Longitudinal changes in ELISPOT results is affected by the use of depleting or nondepleting antibodies as part of the induction process. 13, 15, 16 (b) Most published data with this assay pertain to first time transplant recipients and relatively non-sensitized populations. Expect to see much higher levels of spot formation in those on low-dose immunosuppression greater than 2 years posttransplant and in those who have had 2 or more transplants. (c) Although the SOP states the readout as spots per 300,000 peripheral blood mononuclear cells there can be large changes in the number of PBMC in patients undergoing induction and conventional immunosuppression. 15, 20 Thus, some SOP normalize to CD4 counts although these have yet to used to determine posttransplant outcomes.
Troubleshooting

1.
If an assay suddenly stops working, the substrate solutions or the enzyme-labeled developing antibody may have lost activity and need to be replaced.
2. Two types of background problems are seen in an ELISPOT assay. The first is a diffuse darkening of the membrane. This is most commonly observed when large numbers of cytokine-secreting cells are present in the well resulting in the accumulation of secreted cytokine in the culture supernatant and its subsequent binding to the membrane (see point 10). A diffuse background can be reduced by decreasing the number of cells per well or the duration of the cell incubation. The second type of background problem is the appearance of very small, dark spots that do not reflect secreted cytokine. A trained observer can usually discriminate between real ELISPOTs and these artifacts; real spots have dark centers and light rims (the latter formed by the diffusion of cytokine outward from the secreting cell). Artefactual spots are smaller and of uniform intensity. They may appear when the anticytokine antibodies aggregate, but more frequently are caused by inadequate removal of cells from the plate. Some cells have endogenous phosphatase activity, or nonspecifically bind biotin-labeled antibodies, leading to the formation of these artifacts. This problem can be prevented by allowing the last PBS-Tw wash to sit on the plate for 5 minutes to allow for complete lysis of the cells. 3. To avoid streaks and fuzzy spots, do not move or disturb the plates in the incubator during the cell culture period. 4. To ensure even temperature, do not stack ELISPOT plates during cell incubation. 5. Optimization for reading the ELISPOT plates. The way the plate is read can introduce major variability. Settings on the ELSIPOT reader can make corrections to the automated results after well images have been analyzed, if the image contains artefacts. Artifacts caused by unequal cell distribution, damaged membranes or overdevelopment can lead to inconclusive results. Fortunately, most software will allow manual correction and below is a list of how to manage common problems.
(a) Overdeveloped background: trace the areas to be excised and the machine will compute a new spot count value normalizing count over the area that has been excised. (b) Missed spots: Increase sensitivity (c) Counting too many spots: Decrease sensitivity (d) Not counting faint spots: Increase background balance (e) If large/diffuse spots: Change 'Diffuse processing' to "large" (f) Adjacent spots counted as single: Lower spot separation level (g) Spot clustering: Set spot size to maximum (h) Well is tainted with minute threads/human hairs or other contaminants: Place a checkmark on the 'Fiber Removal' box in count parameters (i) Artifacts around the perimeter of the well: Set the counted area to 90% or lower to avoid counting excessive artefacts around the perimeter. Choose 'normalization' for an accurate count estimate of the excluded area. (j) It is recommended that plates or digital images of the plate be compared at a national or internationally laboratory to determine whether the laboratory ELISPOT reader settings need to be altered to reduce CV between the testing lab and the centralized review laboratory.
SUMMARY
This SOP for interferon gamma ELISPOT is standardized across international laboratories. When followed, it should produce results with acceptable CV. Importantly, a major source of CV variability arises in the process of automated reading of the ELISPOT plate, and we have provided a method to standardize the ELISPOT reading process. For multicenter trials and global standardization, we recommend reading of plates or their digital images at a centralized laboratory to ensure reproducible and comparable results.
